BAK1 and head and neck squamous cell carcinoma: These findings support the hypothesis that combination of NOXA or fenretinide with ABT-263 enhances cell death by interruption of BAK-MCL-1 interaction and functional inhibition of BCL-XL in HNSCC cells (S3 Fig and Fig 8).